Ziyu Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ziyu Yang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Anthony Wayne Orr
Department of Pathology and Translational Pathobiology, LSU Health Shreveport, Shreveport, USA
1 shared publicationBrian G. Coon
Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, Yale University, New Haven, USA
1 shared publication- Carlos Fernández-Hernando
Vascular Biology and Therapeutics Program, Yale University School of Medicine
1 shared publication - Divyesh Joshi
Section of Cardiovascular Medicine, Yale Cardiovascular Research Center, Department of Internal Medicine, School of Medicine, Yale University
1 shared publication Emily Meredith
Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, Yale University, New Haven, USA
1 shared publication- Hanqiang Deng
College of Intelligence Science and Technology, National University of Defense Technology, Changsha 410073, China
1 shared publication
Latest Publications
- Open Access
- 4 September 2024
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 3 (9) , 1035-1048
Endothelial γ-protocadherins inhibit KLF2 and KLF4 to promote atherosclerosis
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Laminar shear stress from blood flow, sensed by vascular endothelial cells, protects from ASCVD by upregulating the transcription factors KLF2 and KLF4, which induces an anti-inflammatory program that promotes vascular resilience. Here we identify clustered γ-protocadherins as therapeutically targetable, potent KLF2 and KLF4 suppressors whose upregulation contributes to ASCVD. Mechanistic studies show that γ-protocadherin cleavage results in translocation of the conserved intracellular domain to the nucleus where it physically associates with and suppresses signaling by the Notch intracellular domain. γ-Protocadherins are elevated in human ASCVD endothelium; their genetic deletion or antibody blockade protects from ASCVD in mice without detectably compromising host defense against bacterial or viral infection. These results elucidate a fundamental mechanism of vascular inflammation and reveal a method to target the endothelium rather than the immune system as a protective strategy in ASCVD.
- 4 September 2024
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 3 (9) , 1035-1048
Open AccessEndothelial γ-protocadherins inhibit KLF2 and KLF4 to promote atherosclerosis
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Laminar shear stress from blood flow, sensed by vascular endothelial cells, protects from ASCVD by upregulating the transcription factors KLF2 and KLF4, which induces an anti-inflammatory program that promotes vascular resilience. Here we identify clustered γ-protocadherins as therapeutically targetable, potent KLF2 and KLF4 suppressors whose upregulation contributes to ASCVD. Mechanistic studies show that γ-protocadherin cleavage results in translocation of the conserved intracellular domain to the nucleus where it physically associates with and suppresses signaling by the Notch intracellular domain. γ-Protocadherins are elevated in human ASCVD endothelium; their genetic deletion or antibody blockade protects from ASCVD in mice without detectably compromising host defense against bacterial or viral infection. These results elucidate a fundamental mechanism of vascular inflammation and reveal a method to target the endothelium rather than the immune system as a protective strategy in ASCVD.